Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab + FOLFIRI in 2nd Line mCRC (ACTIVE)
NCT01144195Phase 2Unknown
- Start
- Sep 2009
- Primary completion
- Dec 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in metastatic colorectal cancer (mCRC). Primary endpoint: Objective Response Rate at 3 years. Status: unknown.
02
Drugs
panitumumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01144195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01144195.